AC Immune's Strategic Bet Pays Off with Promising Brain Drug Data

LAUSANNE, SWITZERLAND – August 20, 2026 – In a significant move that bolsters its strategic pivot towards proprietary assets, AC Immune SA today announced positive preliminary data from the first human trial of its oral drug candidate, ACI-19764. The results show the drug, designed to combat chronic inflammation, is safe, well-tolerated, and—most critically—capable of penetrating the brain. This milestone not only de-risks a key program for the Swiss biotech but also validates its long-term strategy in the highly competitive field of neurodegenerative and inflammatory diseases.

ACI-19764 is an inhibitor of the NLRP3 inflammasome, a protein complex increasingly seen by scientists as a central driver of harmful inflammation in a vast range of conditions, from Alzheimer's to heart disease. The positive Phase 1 data marks a crucial step forward for a class of drugs that many in the industry believe holds 'pipeline in a product' potential, capable of addressing multiple billion-dollar markets.

A Strategic Pivot Validated

For AC Immune, these results are more than just a scientific success; they are a powerful endorsement of its evolving business strategy. While the company has a long history of securing high-value partnerships with pharmaceutical giants like Roche and Eli Lilly, it has recently sharpened its focus on developing its own wholly-owned assets to retain greater long-term value. Today's announcement provides the first major clinical validation for this strategic shift.

"These first-in-human data for ACI-19764 are encouraging, and represent not only an important milestone for this program, but also the wider clinical momentum of our wholly-owned programs," said Martin Zügel, interim CEO of AC Immune, in a statement. The news provided a modest but immediate lift to the company's stock (NASDAQ: ACIU), which has gained nearly 17% over the past year.

This clinical win arrives at a pivotal time. With a cash runway projected to last into the fourth quarter of 2027, supported by milestone payments and a recent workforce reduction, the company is positioning itself for sustainable growth. The success of a proprietary candidate like ACI-19764 strengthens its negotiating position in future partnerships and could significantly enhance shareholder value, moving beyond the shared-risk, shared-reward model of its existing collaborations.

Cracking the Code of Neuro-Inflammation

The scientific community has identified the NLRP3 inflammasome as one of the most compelling drug targets of the decade. Its over-activation is a key factor in the chronic neuro-inflammation that contributes to the progression of diseases like Alzheimer's and Parkinson's. A drug that can safely and effectively block this pathway inside the brain has been a long-sought goal for the industry.

The preliminary Phase 1 data suggests ACI-19764 may have the right profile. The study in healthy volunteers found the drug was safe at doses up to 20mg, with a long half-life of over 30 hours that supports a convenient once-daily pill. Most importantly, tests confirmed the molecule crossed the blood-brain barrier and was present in cerebrospinal fluid, a critical feature for any drug targeting CNS disorders. Furthermore, blinded data showed dose-dependent inhibition of IL-1beta, a key inflammatory protein produced by the NLRP3 pathway, confirming the drug was hitting its target.

This achievement places AC Immune in a competitive but promising landscape. Industry giants like Roche and Novartis, through strategic acquisitions of Inflazome and IFM Tre respectively, are also advancing NLRP3 inhibitors. Other biotechs such as Ventus Therapeutics and NodThera have also reported positive Phase 1 data for their own brain-penetrant candidates. However, with no selective NLRP3 inhibitor yet approved for any disease, the race is wide open. ACI-19764's oral delivery, combined with its demonstrated brain penetration and potent preclinical profile, gives it a strongly competitive position.

Beyond the Brain: A 'Pipeline in a Product'?

While AC Immune's heritage is in neurodegeneration, the company is making a savvy strategic play by exploring ACI-19764's potential far beyond the brain. Underscoring this ambition, the company has already begun dosing a new cohort in its trial: patients with cardiovascular risk factors, including elevated inflammatory markers, type 2 diabetes, or obesity.

This expansion is grounded in strong science. The same NLRP3-driven inflammation that damages neurons is also implicated in the processes that lead to atherosclerosis, insulin resistance, and other metabolic disorders. Preclinical studies of ACI-19764 had already hinted at this broader potential, showing it could inhibit inflammation and even help control weight in animal models.

"Chronic inflammation causes or exacerbates many different conditions... and with ACI-19764 we are able to precisely target the intracellular NLRP3 complex to inhibit the production of potentially harmful downstream pro-inflammatory factors," noted Francesca Capotosti, Senior Vice President of Research at AC Immune.

By gathering early data in a cardiovascular population, AC Immune is positioning ACI-19764 not just as a potential brain drug, but as a versatile anti-inflammatory agent. Success in this cohort, with initial results expected by the end of the year, could open up enormous new markets and transform the drug's value proposition.

The Road Ahead in a Crowded Field

With the market for NLRP3 inhibitors projected to grow to nearly $10 billion by 2034, the stakes are high. The positive safety data from Phase 1 is a critical first step, but the ultimate success of ACI-19764—and its competitors—will hinge on proving efficacy in sick patients. For AC Immune, the path forward is clear but challenging.

The upcoming data from the cardiovascular risk cohort will be the first test of the drug's anti-inflammatory activity in a patient population, providing a crucial early look at its therapeutic potential. These findings, followed by the full data set from the Phase 1/1b trial expected in the first half of 2027, will be intensely scrutinized by investors, potential partners, and the medical community. These readouts will be pivotal in determining whether ACI-19764 can transition from a promising candidate to a transformational treatment option for patients with unmet medical needs.